Adult liver disorders caused by inborn errors of metabolism: Review and update

Molecular Genetics and Metabolism

Volumn 114, Issue 1, 2015, Pages 1-10

  Chanprasert, Sirisak ^a,b   Scaglia, Fernando ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Citrin deficiency; HFE associated hemochromatosis; Inborn errors of metabolism; Wilson disease

Indexed keywords

4 PHENYLBUTYRIC ACID; PENICILLAMINE; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; CALCIUM BINDING PROTEIN; CITRIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; ORGANIC ANION TRANSPORTER;

ADULT; ADULT DISEASE; ADULTHOOD; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOSOMAL RECESSIVE DISORDER; CITRIN DEFICIENCY; CITRULLINEMIA TYPE II; CLINICAL FEATURE; DIET SUPPLEMENTATION; HEMOCHROMATOSIS; HUMAN; INBORN ERROR OF METABOLISM; LIVER DISEASE; LIVER TRANSPLANTATION; LOW CARBOHYDRATE DIET; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; PHLEBOTOMY; PROTEIN DIET; REVIEW; WILSON DISEASE; ALPHA 1-ANTITRYPSIN DEFICIENCY; CHILD; DEFICIENCY; GENETICS; HEPATOLENTICULAR DEGENERATION; LIVER DISEASES; METABOLISM, INBORN ERRORS; PATHOPHYSIOLOGY;

PROTEA;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; CALCIUM-BINDING PROTEINS; CHILD; HEMOCHROMATOSIS; HEPATOLENTICULAR DEGENERATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIVER DISEASES; MEMBRANE PROTEINS; METABOLISM, INBORN ERRORS; ORGANIC ANION TRANSPORTERS;

EID: 84920377894     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.10.011     Document Type: Review

References (133)

1. Ala A., Walker A.P., Ashkan K., Dooley J.S., Schilsky M.L. Wilson's disease. Lancet 2007, 369:397-408.
2. Bull P.C., Thomas G.R., Rommens J.M., Forbes J.R., Cox D.W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 1993, 5:327-337.
3. Petrukhin K., Fischer S.G., Pirastu M., Tanzi R.E., Chernov I., Devoto M., Brzustowicz L.M., Cayanis E., Vitale E., Russo J.J., et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat. Genet. 1993, 5:338-343.
4. Yamaguchi Y., Heiny M.E., Gitlin J.D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun. 1993, 197:271-277.
5. Hsi G., Cox D.W. A comparison of the mutation spectra of Menkes disease and Wilson disease. Hum. Genet. 2004, 114:165-172.
6. Shah A.B., Chernov I., Zhang H.T., Ross B.M., Das K., Lutsenko S., Parano E., Pavone L., Evgrafov O., Ivanova-Smolenskaya I.A., Anneren G., Westermark K., Urrutia F.H., Penchaszadeh G.K., Sternlieb I., Scheinberg I.H., Gilliam T.C., Petrukhin K. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am. J. Hum. Genet. 1997, 61:317-328.
7. Thomas G.R., Forbes J.R., Roberts E.A., Walshe J.M., Cox D.W. The Wilson disease gene: spectrum of mutations and their consequences. Nat. Genet. 1995, 9:210-217.
8. Lang P.A., Schenck M., Nicolay J.P., Becker J.U., Kempe D.S., Lupescu A., Koka S., Eisele K., Klarl B.A., Rubben H., Schmid K.W., Mann K., Hildenbrand S., Hefter H., Huber S.M., Wieder T., Erhardt A., Haussinger D., Gulbins E., Lang F. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat. Med. 2007, 13:164-170.
9. Ostapowicz G., Fontana R.J., Schiodt F.V., Larson A., Davern T.J., Han S.H., McCashland T.M., Shakil A.O., Hay J.E., Hynan L., Crippin J.S., Blei A.T., Samuel G., Reisch J., Lee W.M., U.S.A.L.F.S.Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002, 137:947-954.
10. Walshe J.M., Waldenstrom E., Sams V., Nordlinder H., Westermark K. Abdominal malignancies in patients with Wilson's disease. QJM 2003, 96:657-662.
11. Wilkinson M.L., Portmann B., Williams R. Wilson's disease and hepatocellular carcinoma: possible protective role of copper. Gut 1983, 24:767-771.
12. Alt E.R., Sternlieb I., Goldfischer S. The cytopathology of metal overload. International review of experimental pathology 1990, 31:165-188.
13. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 1968, 55:354-367.
14. Schilsky M.L., Scheinberg I.H., Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991, 100:762-767.
15. Walshe J.M. Wilson's disease. The presenting symptoms. Arch. Dis. Child. 1962, 37:253-256.
16. Oder W., Grimm G., Kollegger H., Ferenci P., Schneider B., Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol. 1991, 238:281-287.
17. Dening T.R., Berrios G.E. Wilson's disease. Psychiatric symptoms in 195 cases. Arch. Gen. Psychiatry 1989, 46:1126-1134.
18. Dobyns W.B., Goldstein N.P., Gordon H. Clinical spectrum of Wilson's disease (hepatolenticular degeneration). Mayo Clin. Proc. 1979, 54:35-42.
19. Frommer D., Morris J., Sherlock S., Abrams J., Newman S. Kayser-Fleischer-like rings in patients without Wilson's disease. Gastroenterology 1977, 72:1331-1335.
20. Fleming C.R., Dickson E.R., Wahner H.W., Hollenhorst R.W., McCall J.T. Pigmented corneal rings in non-Wilsonian liver disease. Ann. Intern. Med. 1977, 86:285-288.
21. Yarze J.C., Martin P., Munoz S.J., Friedman L.S. Wilson's disease: current status. Am. J. Med. 1992, 92:643-654.
22. Pfeiffer R.F. Wilson's disease. Semin. Neurol. 2007, 27:123-132.
23. Bearn A.G., Mc K.V. Azure lunulae; an unusual change in the fingernails in two patients with hepatolenticular degeneration. JAMA 1958, 166:904-906.
24. Sozeri E., Feist D., Ruder H., Scharer K. Proteinuria and other renal functions in Wilson's disease. Pediatr. Nephrol. 1997, 11:307-311.
25. Kalra V., Mahajan S., Kesarwani P.K. Rare presentation of Wilson's disease: a case report. Int. Urol. Nephrol. 2004, 36:289-291.
26. Schilsky M.L. Wilson disease: new insights into pathogenesis, diagnosis, and future therapy. Curr. Gastroenterol. Rep. 2005, 7:26-31.
27. Gitlin J.D. Wilson disease. Gastroenterology 2003, 125:1868-1877.
28. Steindl P., Ferenci P., Dienes H.P., Grimm G., Pabinger I., Madl C., Maier-Dobersberger T., Herneth A., Dragosics B., Meryn S., Knoflach P., Granditsch G., Gangl A. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997, 113:212-218.
29. Nuttall K.L., Palaty J., Lockitch G. Reference limits for copper and iron in liver biopsies. Ann. Clin. Lab. Sci. 2003, 33:443-450.
30. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. 1956, 21:487-495.
31. Perrett D. The metabolism and pharmacology of D-penicillamine in man. J. Rheumatol. Suppl. 1981, 7:41-50.
32. Brewer G.J., Terry C.A., Aisen A.M., Hill G.M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch. Neurol. 1987, 44:490-493.
33. Roberts E.A., Schilsky M.L., Division of Gastroenterology and Nutrition, H.f.S.C.T.O.C. A practice guideline on Wilson disease. Hepatology 2003, 37:1475-1492.
34. Scheinberg I.H., Jaffe M.E., Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N. Engl. J. Med. 1987, 317:209-213.
35. Santos Silva E.E., Sarles J., Buts J.P., Sokal E.M. Successful medical treatment of severely decompensated Wilson disease. J. Pediatr. 1996, 128:285-287.
36. Brewer G.J., Hedera P., Kluin K.J., Carlson M., Askari F., Dick R.B., Sitterly J., Fink J.K. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 2003, 60:379-385.
37. Eghtesad B., Nezakatgoo N., Geraci L.C., Jabbour N., Irish W.D., Marsh W., Fung J.J., Rakela J. Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl. Surg. 1999, 5:467-474.
38. Schumacher G., Platz K.P., Mueller A.R., Neuhaus R., Steinmuller T., Bechstein W.O., Becker M., Luck W., Schuelke M., Neuhaus P. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin. Transplant. 1997, 11:217-224.
39. Maurice N., Perlmutter D.H. Novel treatment strategies for liver disease due to alpha1-antitrypsin deficiency. Clin. Transl. Sci. 2012, 5:289-294.
40. Kelly E., Greene C.M., Carroll T.P., McElvaney N.G., O'Neill S.J. Alpha-1 antitrypsin deficiency. Respir. Med. 2010, 104:763-772.
41. Blanco I., de Serres F.J., Fernandez-Bustillo E., Lara B., Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur. Respir. J. 2006, 27:77-84.
42. de Serres F.J., Blanco I., Fernandez-Bustillo E. Estimated numbers and prevalence of PI*S and PI*Z deficiency alleles of alpha1-antitrypsin deficiency in Asia. Eur. Respir. J. 2006, 28:1091-1099.
43. de Serres F.J., Blanco I., Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin. Genet. 2003, 64:382-397.
44. Nelson D.R., Teckman J., Di Bisceglie A.M., Brenner D.A. Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency. Clin. Gastroenterol. Hepatol. 2012, 10:575-580.
45. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med. 1976, 294:1316-1321.
46. Clark V.C., Dhanasekaran R., Brantly M., Rouhani F., Schreck P., Nelson D.R. Liver test results do not identify liver disease in adults with alpha(1)-antitrypsin deficiency. Clin. Gastroenterol. Hepatol. 2012, 10:1278-1283.
47. Cox D.W., Smyth S. Risk for liver disease in adults with alpha 1-antitrypsin deficiency. Am. J. Med. 1983, 74:221-227.
48. Carrell R.W., Lomas D.A. Alpha1-antitrypsin deficiency-a model for conformational diseases. N. Engl. J. Med. 2002, 346:45-53.
49. McBean J., Sable A., Maude J., Robinson-Bostom L. Alpha1-antitrypsin deficiency panniculitis. Cutis 2003, 71:205-209.
50. Strife C.F., Hug G., Chuck G., McAdams A.J., Davis C.A., Kline J.J. Membranoproliferative glomerulonephritis and alpha 1-antitrypsin deficiency in children. Pediatrics 1983, 71:88-92.
51. Fearnley I.R., Spalton D.J., Ward A.M., Slavin B., Muncey F. Alpha 1-antitrypsin phenotypes in acute anterior uveitis. Br. J. Ophthalmol. 1988, 72:636-639.
52. Cox D.W. Alpha 1-antitrypsin: a guardian of vascular tissue. Mayo Clin. Proc. 1994, 69:1123-1124.
53. Mazodier P., Elzouki A.N., Segelmark M., Eriksson S. Systemic necrotizing vasculitides in severe alpha1-antitrypsin deficiency. QJM 1996, 89:599-611.
54. Barnett V.T., Sekosan M., Khurshid A. Wegener's granulomatosis and alpha1-antitrypsin-deficiency emphysema: proteinase-related diseases. Chest 1999, 116:253-255.
55. Lonardo A., Medicina D., Leonelli M., Bagni A., Callea F. Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida). Eur. J. Gastroenterol. Hepatol. 2002, 14:1389-1392.
56. Huber R., Carrell R.W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989, 28:8951-8966.
57. Brantly M., Nukiwa T., Crystal R.G. Molecular basis of alpha-1-antitrypsin deficiency. Am. J. Med. 1988, 84:13-31.
58. Carlson J.A., Rogers B.B., Sifers R.N., Finegold M.J., Clift S.M., DeMayo F.J., Bullock D.W., Woo S.L. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J. Clin. Invest. 1989, 83:1183-1190.
59. Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992, 357:605-607.
60. Sivasothy P., Dafforn T.R., Gettins P.G., Lomas D.A. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J. Biol. Chem. 2000, 275:33663-33668.
61. Dafforn T.R., Mahadeva R., Elliott P.R., Sivasothy P., Lomas D.A. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J. Biol. Chem. 1999, 274:9548-9555.
62. Teckman J.H., An J.K., Blomenkamp K., Schmidt B., Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G851-862.
63. Teckman J.H., Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr. Gastroenterol. Rep. 2014, 16:367.
64. Burrows J.A., Willis L.K., Perlmutter D.H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1796-1801.
65. Saheki T., Inoue K., Tushima A., Mutoh K., Kobayashi K. Citrin deficiency and current treatment concepts. Mol. Genet. Metab. 2010, 100(Suppl. 1):S59-64.
66. Ikeda S., Yazaki M., Takei Y., Ikegami T., Hashikura Y., Kawasaki S., Iwai M., Kobayashi K., Saheki T. Type II (adult onset) citrullinaemia: clinical pictures and the therapeutic effect of liver transplantation. J. Neurol. Neurosurg. Psychiatry 2001, 71:663-670.
67. Saheki T., Kobayashi K., Inoue I. Hereditary disorders of the urea cycle in man: biochemical and molecular approaches. Rev. Physiol. Biochem. Pharmacol. 1987, 108:21-68.
68. Kobayashi K., Saheki T., Imamura Y., Noda T., Inoue I., Matuo S., Hagihara S., Nomiyama H., Jinno Y., Shimada K. Messenger RNA coding for argininosuccinate synthetase in citrullinemia. Am. J. Hum. Genet. 1986, 38:667-680.
69. Kobayashi K., Shaheen N., Kumashiro R., Tanikawa K., O'Brien W.E., Beaudet A.L., Saheki T. A search for the primary abnormality in adult-onset type II citrullinemia. Am. J. Hum. Genet. 1993, 53:1024-1030.
70. Kobayashi K., Sinasac D.S., Iijima M., Boright A.P., Begum L., Lee J.R., Yasuda T., Ikeda S., Hirano R., Terazono H., Crackower M.A., Kondo I., Tsui L.C., Scherer S.W., Saheki T. The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat. Genet. 1999, 22:159-163.
71. Tazawa Y., Kobayashi K., Ohura T., Abukawa D., Nishinomiya F., Hosoda Y., Yamashita M., Nagata I., Kono Y., Yasuda T., Yamaguchi N., Saheki T. Infantile cholestatic jaundice associated with adult-onset type II citrullinemia. J. Pediatr. 2001, 138:735-740.
72. Ohura T., Kobayashi K., Tazawa Y., Nishi I., Abukawa D., Sakamoto O., Iinuma K., Saheki T. Neonatal presentation of adult-onset type II citrullinemia. Hum. Genet. 2001, 108:87-90.
73. Tomomasa T., Kobayashi K., Kaneko H., Shimura H., Fukusato T., Tabata M., Inoue Y., Ohwada S., Kasahara M., Morishita Y., Kimura M., Saheki T., Morikawa A. Possible clinical and histologic manifestations of adult-onset type II citrullinemia in early infancy. J. Pediatr. 2001, 138:741-743.
74. Saheki T., Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J. Hum. Genet. 2002, 47:333-341.
75. Song Y.Z., Deng M., Chen F.P., Wen F., Guo L., Cao S.L., Gong J., Xu H., Jiang G.Y., Zhong L., Kobayashi K., Saheki T., Wang Z.N. Genotypic and phenotypic features of citrin deficiency: five-year experience in a Chinese pediatric center. Int. J. Mol. Med. 2011, 28:33-40.
76. Treepongkaruna S., Jitraruch S., Kodcharin P., Charoenpipop D., Suwannarat P., Pienvichit P., Kobayashi K., Wattanasirichaigoon D. Neonatal intrahepatic cholestasis caused by citrin deficiency: prevalence and SLC25A13 mutations among Thai infants. BMC Gastroenterol. 2012, 12:141.
77. Chew H.B., Ngu L.H., Zabedah M.Y., Keng W.T., Balasubramaniam S., Hanifah M.J., Kobayashi K. Neonatal intrahepatic cholestasis associated with citrin deficiency (NICCD): a case series of 11 Malaysian patients. J. Inherit. Metab. Dis. 2010, 33(Suppl. 3):S489-495.
78. Fiermonte G., Soon D., Chaudhuri A., Paradies E., Lee P.J., Krywawych S., Palmieri F., Lachmann R.H. An adult with type 2 citrullinemia presenting in Europe. N. Engl. J. Med. 2008, 358:1408-1409.
79. Fiermonte G., Parisi G., Martinelli D., De Leonardis F., Torre G., Pierri C.L., Saccari A., Lasorsa F.M., Vozza A., Palmieri F., Dionisi-Vici C. A new Caucasian case of neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD): a clinical, molecular, and functional study. Mol. Genet. Metab. 2011, 104:501-506.
80. Vitoria I., Dalmau J., Ribes C., Rausell D., Garcia A.M., Lopez-Montiel J., Rubio V. Citrin deficiency in a Romanian child living in Spain highlights the worldwide distribution of this defect and illustrates the value of nutritional therapy. Mol. Genet. Metab. 2013, 110:181-183.
81. Dimmock D., Maranda B., Dionisi-Vici C., Wang J., Kleppe S., Fiermonte G., Bai R., Hainline B., Hamosh A., O'Brien W.E., Scaglia F., Wong L.J. Citrin deficiency, a perplexing global disorder. Mol. Genet. Metab. 2009, 96:44-49.
82. Wang J.S., Wang X.H., Zheng Y.J., Fu H.Y., Chen R., Lu Y., Fang L.J., Saheki T., Kobayashi K. Biochemical characteristics of neonatal cholestasis induced by citrin deficiency. World J. Gastroenterol. 2012, 18:5601-5607.
83. Lee B.H., Jin H.Y., Kim G.H., Choi J.H., Yoo H.W. Nonalcoholic fatty liver disease in 2 siblings with adult-onset type II citrullinemia. J. Pediatr. Gastroenterol. Nutr. 2010, 50:682-685.
84. Erez A., Shchelochkov O.A., Plon S.E., Scaglia F., Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am. J. Hum. Genet. 2011, 88:402-421.
85. Saheki T., Kobayashi K., Terashi M., Ohura T., Yanagawa Y., Okano Y., Hattori T., Fujimoto H., Mutoh K., Kizaki Z., Inui A. Reduced carbohydrate intake in citrin-deficient subjects. J. Inherit. Metab. Dis. 2008, 31:386-394.
86. Palmieri L., Pardo B., Lasorsa F.M., del Arco A., Kobayashi K., Iijima M., Runswick M.J., Walker J.E., Saheki T., Satrustegui J., Palmieri F. Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. EMBO J. 2001, 20:5060-5069.
87. Moriyama M., Li M.X., Kobayashi K., Sinasac D.S., Kannan Y., Iijima M., Horiuchi M., Tsui L.C., Tanaka M., Nakamura Y., Saheki T. Pyruvate ameliorates the defect in ureogenesis from ammonia in citrin-deficient mice. J. Hepatol. 2006, 44:930-938.
88. Saheki T., Inoue K., Ono H., Tushima A., Katsura N., Yokogawa M., Yoshidumi Y., Kuhara T., Ohse M., Eto K., Kadowaki T., Sinasac D.S., Kobayashi K. Metabolomic analysis reveals hepatic metabolite perturbations in citrin/mitochondrial glycerol-3-phosphate dehydrogenase double-knockout mice, a model of human citrin deficiency. Mol. Genet. Metab. 2011, 104:492-500.
89. Saheki T., Iijima M., Li M.X., Kobayashi K., Horiuchi M., Ushikai M., Okumura F., Meng X.J., Inoue I., Tajima A., Moriyama M., Eto K., Kadowaki T., Sinasac D.S., Tsui L.C., Tsuji M., Okano A., Kobayashi T. Citrin/mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency. J. Biol. Chem. 2007, 282:25041-25052.
90. Yazaki M., Takei Y., Kobayashi K., Saheki T., Ikeda S. Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adult-onset type II citrullinemia (CTLN2). Intern. Med. 2005, 44:188-195.
91. Zhao Y., Zhang J., Li H., Li Y., Ren J., Luo M., Zheng X. An NADPH sensor protein (HSCARG) down-regulates nitric oxide synthesis by association with argininosuccinate synthetase and is essential for epithelial cell viability. J. Biol. Chem. 2008, 283:11004-11013.
92. Dimmock D., Kobayashi K., Iijima M., Tabata A., Wong L.J., Saheki T., Lee B., Scaglia F. Citrin deficiency: a novel cause of failure to thrive that responds to a high-protein, low-carbohydrate diet. Pediatrics 2007, 119:e773-777.
93. Fukushima K., Yazaki M., Nakamura M., Tanaka N., Kobayashi K., Saheki T., Takei H., Ikeda S. Conventional diet therapy for hyperammonemia is risky in the treatment of hepatic encephalopathy associated with citrin deficiency. Intern. Med. 2010, 49:243-247.
94. Mutoh K., Kurokawa K., Kobayashi K., Saheki T. Treatment of a citrin-deficient patient at the early stage of adult-onset type II citrullinaemia with arginine and sodium pyruvate. J. Inherit. Metab. Dis. 2008, 31(Suppl. 2):S343-347.
95. Kasahara M., Ohwada S., Takeichi T., Kaneko H., Tomomasa T., Morikawa A., Yonemura K., Asonuma K., Tanaka K., Kobayashi K., Saheki T., Takeyoshi I., Morishita Y. Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. Transplantation 2001, 71:157-159.
96. Tamamori A., Okano Y., Ozaki H., Fujimoto A., Kajiwara M., Fukuda K., Kobayashi K., Saheki T., Tagami Y., Yamano T. Neonatal intrahepatic cholestasis caused by citrin deficiency: severe hepatic dysfunction in an infant requiring liver transplantation. Eur. J. Pediatr. 2002, 161:609-613.
97. Shigeta T., Kasahara M., Kimura T., Fukuda A., Sasaki K., Arai K., Nakagawa A., Nakagawa S., Kobayashi K., Soneda S., Kitagawa H. Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor. Pediatr. Transplant. 2010, 14:E86-88.
98. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010, 139:393-408. (408 e391-392).
99. Gulati V., Harikrishnan P., Palaniswamy C., Aronow W.S., Jain D., Frishman W.H. Cardiac involvement in hemochromatosis. Cardiol. Rev. 2014, 22:56-68.
100. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341:1986-1995.
101. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., Dormishian F., Domingo R., Ellis M.C., Fullan A., Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P., Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C., Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E., Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T., Risch N.J., Bacon B.R., Wolff R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996, 13:399-408.
102. Cherfane C.E., Hollenbeck R.D., Go J., Brown K.E. Hereditary hemochromatosis: missed diagnosis or misdiagnosis?. Am. J. Med. 2013, 126:1010-1015.
103. Barton J.C. Hemochromatosis and iron overload: from bench to clinic. Am. J. Med. Sci. 2013, 346:403-412.
104. L.European Association For The Study Of The EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol. 2010, 53:3-22.
105. Walsh A., Dixon J.L., Ramm G.A., Hewett D.G., Lincoln D.J., Anderson G.J., Subramaniam V.N., Dodemaide J., Cavanaugh J.A., Bassett M.L., Powell L.W. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin. Gastroenterol. Hepatol. 2006, 4:1403-1410.
106. McDonnell S.M., Preston B.L., Jewell S.A., Barton J.C., Edwards C.Q., Adams P.C., Yip R. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am. J. Med. 1999, 106:619-624.
107. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 1985, 313:1256-1262.
108. Deugnier Y.M., Guyader D., Crantock L., Lopez J.M., Turlin B., Yaouanq J., Jouanolle H., Campion J.P., Launois B., Halliday J.W., et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993, 104:228-234.
109. Singh P., Kaur H., Lerner R.G., Patel R., Rafiyath S.M., Singh Lamba G. Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Rev. J. Gastrointest. Cancer 2012, 43:36-39.
110. Wood M.J., Gadd V.L., Powell L.W., Ramm G.A., Clouston A.D. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology 2014, 59:848-857.
111. Hatunic M., Finucane F.M., Brennan A.M., Norris S., Pacini G., Nolan J.J. Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism 2010, 59:380-384.
112. McClain D.A., Abraham D., Rogers J., Brady R., Gault P., Ajioka R., Kushner J.P. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006, 49:1661-1669.
113. Rahier J., Loozen S., Goebbels R.M., Abrahem M. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987, 30:5-12.
114. Kishimoto M., Endo H., Hagiwara S., Miwa A., Noda M. Immunohistochemical findings in the pancreatic islets of a patient with transfusional iron overload and diabetes: case report. J. Med. Invest. 2010, 57:345-349.
115. Carroll G.J., Breidahl W.H., Bulsara M.K., Olynyk J.K. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum. 2011, 63:286-294.
116. Sahinbegovic E., Dallos T., Aigner E., Axmann R., Manger B., Englbrecht M., Schoniger-Hekele M., Karonitsch T., Stamm T., Farkas M., Karger T., Stolzel U., Keysser G., Datz C., Schett G., Zwerina J. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010, 62:3792-3798.
117. Husar-Memmer E., Stadlmayr A., Datz C., Zwerina J. HFE-related hemochromatosis: an update for the rheumatologist. Curr. Rheumatol. Rep. 2014, 16:393.
118. Wasserman A.J., Richardson D.W., Baird C.L., Wyso E.M. Cardiac hemochromatosis simulating constrictive pericarditis. Am. J. Med. 1962, 32:316-323.
119. James T.N. Pathology of the cardiac conduction system in hemochromatosis. N. Engl. J. Med. 1964, 271:92-94.
120. Aronow W.S., Meister L., Kent J.R. Atrioventricular block in familial hemochromatosis treated by permanent synchronous pacemaker. Arch. Intern. Med. 1969, 123:433-435.
121. Conrad M.E., Umbreit J.N. Pathways of iron absorption. Blood Cells Mol. Dis. 2002, 29:336-355.
122. Ward D.M., Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim. Biophys. Acta 2012, 1823:1426-1433.
123. Yeh K.Y., Yeh M., Mims L., Glass J. Iron feeding induces ferroportin 1 and hephaestin migration and interaction in rat duodenal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G55-65.
124. Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998, 35:35-54.
125. Roy C.N. An update on iron homeostasis: make new friends, but keep the old. Am. J. Med. Sci. 2013, 346:413-419.
126. Adams P.C., Reboussin D.M., Barton J.C., McLaren C.E., Eckfeldt J.H., McLaren G.D., Dawkins F.W., Acton R.T., Harris E.L., Gordeuk V.R., Leiendecker-Foster C., Speechley M., Snively B.M., Holup J.L., Thomson E., Sholinsky P., Hemochromatosis, I.Iron Overload Screening Study Research Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 2005, 352:1769-1778.
127. Bassett M.L., Halliday J.W., Ferris R.A., Powell L.W. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984, 87:628-633.
128. Adams P.C., Passmore L., Chakrabarti S., Reboussin D.M., Acton R.T., Barton J.C., McLaren G.D., Eckfeldt J.H., Dawkins F.W., Gordeuk V.R., Harris E.L., Leiendecker-Foster C., Gossman E., Sholinsky P., Hemochromatosis, I.Iron Overload Screening Study Research Liver diseases in the hemochromatosis and iron overload screening study. Clin. Gastroenterol. Hepatol. 2006, 4:918-923. (quiz 807).
129. Allen K.J., Gurrin L.C., Constantine C.C., Osborne N.J., Delatycki M.B., Nicoll A.J., McLaren C.E., Bahlo M., Nisselle A.E., Vulpe C.D., Anderson G.J., Southey M.C., Giles G.G., English D.R., Hopper J.L., Olynyk J.K., Powell L.W., Gertig D.M. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 2008, 358:221-230.
130. Deugnier Y., Turlin B. Pathology of hepatic iron overload. Semin. Liver Dis. 2011, 31:260-271.
131. Crawford D.H., Fletcher L.M., Hubscher S.G., Stuart K.A., Gane E., Angus P.W., Jeffrey G.P., McCaughan G.W., Kerlin P., Powell L.W., Elias E.E. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 2004, 39:1655-1662.
132. Kowdley K.V., Brandhagen D.J., Gish R.G., Bass N.M., Weinstein J., Schilsky M.L., Fontana R.J., McCashland T., Cotler S.J., Bacon B.R., Keeffe E.B., Gordon F., Polissar N., R.National Hemochromatosis Transplant Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005, 129:494-503.
133. Bardou-Jacquet E., Philip J., Lorho R., Ropert M., Latournerie M., Houssel-Debry P., Guyader D., Loreal O., Boudjema K., Brissot P. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 2014, 59:839-847.